• Login
    View Item 
    •   DSpace Home
    • SUNY Brockport
    • Events/Conferences
    • 2015 SUNY Undergraduate Research Conference
    • View Item
    •   DSpace Home
    • SUNY Brockport
    • Events/Conferences
    • 2015 SUNY Undergraduate Research Conference
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Effect of histone deacetylase inhibition on radiosensitivity of primary human fibroblasts following charged particle irradiation

    Thumbnail
    View/Open
    surc/2015/schedule/250/fulltext (1).pdf (19.88Kb)
    Date
    2015-04-10
    Author
    Millings, Jonathan M.
    Daniels, Benjamin
    Chavannes, Leonard
    Kolodiuk, Lucia
    Salidad, Katherine Z.
    Johnson, Alicia M.
    Keszenman, Deborah
    Wilson, Paul F.
    Bennett, Paula
    Metadata
    Show full item record
    Subject
    Biology
    Radiobiology
    Histone Deacetylases
    Abstract
    Present-day cancer researchers are seeking more precise therapy options for cancer patients which can deliver the most potent effect to tumors, while protecting the surrounding healthy tissues. Our lab studied how tumors respond to combinations of chemotherapy drugs (specifically, histone deacetylase inhibitors or HDACi’s) and protons, a type of charged particle ionizing radiation used in radiotherapy. HDACi’s prevent histone deacetylase enzymes from compacting nuclear DNA, thus maintaining DNA in a more “open” configuration. We were interested in whether the HDACi 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl] benzamide (M344) would increase the radiosensitivity of irradiated cells, making them more susceptible to DNA damage through the induction of lethal DNA double strand breaks (DSBs). We used neonatal human fibroblasts (NFF28) as our cell model. Cells were pre-treated with the HDACi SAHA/Vorinostat - a current FDA-approved chemotherapeutic drug and established radiosensitizer - or the experimental HDACi M344. This treatment was followed by irradiation with 200 MeV protons at the NASA Space Radiation Laboratory with doses between 0–400 cGy. The vehicle control (DMSO-treated) and HDACi-treated cells showed a biphasic dose response with a higher slope at low doses (0–50 cGy), indicating low dose hypersensitivity, followed by a reduced slope at higher doses (100–400cGy). Cells treated with SAHA showed significantly increased levels of DNA DSBs and radiosensitization, however, M344 dose responses were similar to our vehicle control cells with almost no radiosensitizing effect on normal cells, regardless of dosage. These results demonstrated that M344 may be an attractive chemotherapeutic adjuvant for proton radiotherapy by sparing normal tissues.
    URI
    http://hdl.handle.net/1951/72692
    Collections
    • 2015 SUNY Undergraduate Research Conference [409]

    SUNY Digital Repository Support
    DSpace software copyright © 2002-2022  DuraSpace
    Contact Us | Send Feedback
    DSpace Express is a service operated by 
    Atmire NV
     

     


    SUNY Digital Repository Support
    DSpace software copyright © 2002-2022  DuraSpace
    Contact Us | Send Feedback
    DSpace Express is a service operated by 
    Atmire NV